Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on March 1, 2007

Stroke. 2007
Published online before print March 1, 2007, doi: 10.1161/01.STR.0000260090.90508.3e
A more recent version of this article appeared on April 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/4/1229    most recent
01.STR.0000260090.90508.3ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lip, G. Y.H.
Right arrow Articles by Hart, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lip, G. Y.H.
Right arrow Articles by Hart, R. G.
Related Collections
Right arrow Other Vascular biology

Submitted on October 18, 2006
Accepted on November 23, 2006

High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation. Relationship to Stroke Risk Factors, Stroke Risk Stratification Schema, and Prognosis

Gregory Y.H. Lip MD*; Jeetesh V. Patel PhD; Elizabeth Hughes MD; and Robert G. Hart MD

From Haemostasis Thrombosis and Vascular Biology Unit (G.Y.H.L., J.V.P., E.H.), University Department of Medicine, City Hospital, Birmingham, England, UK; University of Texas Health Science Center (R.G.H.), San Antonio, Tex.

* To whom correspondence should be addressed. E-mail: g.y.h.lip{at}bham.ac.uk.

Background and Purpose--There is now considerable evidence that atrial fibrillation is associated with an inflammatory state. We tested the hypothesis that plasma levels of C-reactive protein (CRP; an index of inflammation) and soluble CD40 ligand (an index of platelet activation, with links to inflammation) could be related to 3 established stroke risk stratification schema (SPAF, CHADS2, and NICE), recognized stroke risk factors or other cardiovascular disease, and prognosis.

Methods--We studied 880 subjects with atrial fibrillation recruited from subjects receiving aspirin 325 mg/d (alone or combined with fixed inefficacious doses of warfarin) from the Stroke Prevention in Atrial Fibrillation (SPAF) III clinical trial. CRP and soluble CD40 ligand were measured by enzyme-linked immunosorbent assay.

Results--With respect to the SPAF III stroke risk stratification criteria, those with moderate to high risk had the highest levels of CRP (Kruskal Wallis test, P<0.001), but those with the highest risk had the lowest levels of soluble CD40 ligand (P=0.01). Similarly, CRP levels increased in a positive fashion with increasing stroke risk with respect to the CHADS2 and NICE risk stratification criteria, whereas soluble CD40 ligand levels were negatively associated with stroke risk. CRP levels were higher among those patients with raised body mass index, diabetes, hypertension, ischemic heart disease, peripheral vascular disease, and recent heart failure, but not those with thromboembolism. Patients were followed-up for a mean time of 453 (standard deviation, 229) days, and all-cause mortality (log rank test, P=0.001), and vascular events (P=0.05), but not stroke, were more common in patients with high CRP levels. Soluble CD40 ligand levels were not related to stroke, vascular events, or all-cause mortality.

Conclusion--Among atrial fibrillation patients, CRP was positively correlated to stroke risk and related to stroke risk factors and prognosis (mortality, vascular events). Soluble CD40 ligand levels were lowest in those at moderate to high risk of stroke and not related to prognosis. The use of CRP in risk stratification for atrial fibrillation merits further study.


Key words: atrial fibrillation • C-reactive protein • soluble CD40 ligand • stroke




This article has been cited by other articles:


Home page
QJMHome page
J. Sanchez-Quinones, F. Marin, V. Roldan, and G.Y.H. Lip
The impact of statin use on atrial fibrillation
QJM, August 24, 2008; (2008) hcn101v1.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
C. J Boos and G. Y H Lip
Inflammation and atrial fibrillation: cause or effect?
Heart, February 1, 2008; 94(2): 133 - 134.
[Full Text] [PDF]


Home page
EuropaceHome page
H. Duygu, V. Barisik, H. Kurt, U. Turk, E. Ercan, and S. Kose
Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation
Europace, February 1, 2008; 10(2): 210 - 214.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. Choudhury, B. Freestone, J. Patel, and G. Y. H. Lip
Relationship of Soluble CD40 Ligand to Vascular Endothelial Growth Factor, Angiopoietins, and Tissue Factor in Atrial Fibrillation: A Link Among Platelet Activation, Angiogenesis, and Thrombosis?
Chest, December 1, 2007; 132(6): 1913 - 1919.
[Abstract] [Full Text] [PDF]